GUANGZHOU, China --- Bio-Thera Solutions (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and biosesesimilars,today announced the company has reached an exclusivecommercialization and license agreement with IntasPharmaceuticals for BAT2506, a golimum...
DetailsGuangzhou, China/Budapest, Hungary– # October 9,2024 – Bio-Thera Solutions (688177:SH; “Bio-Thera”), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies andbiosesesimilars, and Gedeon Richter (“Richter”) announce today they have reached anexclusive comme...
Comparable clinical efficacy and safety in Treatment Period 2 (TP2, Week 24-48) is maintained after switch from reference tocilizumab to TOFIDENCE (BAT1806/BIIB800) Phase 3 clinical data in totality demonstrates biosesesimilarity between TOFIDENCE (BAT1806/BIIB800) and reference tocilizumab before and a...
GUANGZHOU, China and MOSCOW, Russia --- Bio-Thera Solutions, Ltd (688177:SH), a commercial-stagebiopharmaceutical company developing a pipeline of innovative therapies and apipeline of biosesesimilars, today announced the company hasreached licensing and supply agreements with PharmaparkLLC, for BAT 23 ...
